1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...
We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...
A new interdisciplinary study at the University of Delaware seeks to study AD by examining changes in the arteries and brain ...
Professor Nancy Ip discusses her groundbreaking neuroscience research, focusing on neurotrophic factors and innovative ...
Researchers map the unique genetic regulation of proteins in human cerebrospinal fluid, identifying potential targets for ...
Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ in rare pediatric disease HLHS has achieved more than 80% enrollmentPositive Type C ...
Arsenal have helped fund Park Theatre’s Reminiscence Group for people with dementia. Stephen Whittle tells us about them ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback